Lonza Sells Off Its Capsules Division To British Firm

2026-03-09 12:07:38

Abstract generation in progress

(MENAFN- Swissinfo) Lonza is selling its capsules and health ingredients business to the British private equity firm Lone Star Funds. The deal, worth CHF2.3 billion ($3 billion), is expected to be completed in the second half of 2026. Select your language

Generated with artificial intelligence. Listening: Lonza sells off its capsules division to British firm This content was published on March 7, 2026 - 11:45 2 minutes Keystone-SDA

Français fr Lonza vend sa division dédiée aux capsules Original Read more: Lonza vend sa division dédiée aux cap

** +Get the most important news from Switzerland in your inbox

Lonza will receive CHF1.7 billion in cash immediately and will retain a 40% stake in its capsules and health ingredients (CHI) business, with a preferential right on any future sale, the Basel-based pharma supplier said in a press release on Wednesday.

Lonza plans to use the CHF1.7 billion to finance organic growth, make targeted acquisitions and strengthen its technological and industrial capacities in contract development and manufacturing organisation (CDMO), the statement said.

In addition, CHF500 million will be redistributed to shareholders through a share buyback programme once the initial payment has been received. The total gain from the sale of the CHI division, including the initial product and all future products, should amount to at least CHF3 billion.

More More Healthcare innovation Swiss pharma’s global success meets worries at home

This content was published on Feb 13, 2026 Switzerland’s two biggest pharmaceutical companies are doing well. Why is the country so worried?

Read more: Swiss pharma’s global success meets worries at **

MENAFN07032026000210011054ID1110831343

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.